Shanghai Pharmaceuticals (SHA:601607, HKG:2607) obtained a drug registration certificate from China's National Medical Products Administration for paclitaxel injection, according to a Tuesday disclosure on the Shanghai bourse.

The drug is intended for the treatment of advanced ovarian cancer, breast cancer, non-small cell lung cancer and AIDS-related Kaposi's sarcoma.